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ABSTRACT 
Retinoids are used to treat various skin diseases. They add valuable impact of when used early in the treatment of dermatological conditions. 
Overall vitamin A derivatives are underused, with isotretinoin is the most used. This paper aims to develop prescribers’ knowledge about their 
benefits, to improve their usability and aids in alleviating patient concerns to improve therapeutic outcomes in dermatological conditions. In acne 
vulgaris, adapalene gel and tretinoin cream showed equal efficacy. In psoriasis the combination of acitretin and PUVA was superior to PUVA alone. 
Acitretin showed a reduction of 41% in the Nail Psoriasis Severity Index and similar efficacy to potent steroids and calcipotriol. In chronic hand 
eczema, alitretinoin showed 50% improvement in patient’s refractory to steroid treatment. In photoaging and aging, retinoids were shown to 
increase the synthesis and decrease the degradation rate of collagen and hyaluronate, reducing the impact of aging. In rosacea, topical and systemic 
isotretinoin showed complete remission in 24% of the patients compared to only 14 % with antibiotics (metronidazole and doxycycline). In lichen 
planus, isotretinoin demonstrated clinical and histopathological efficacy. In cutaneous T-cell lymphoma, bexarotene used alone or with PUVA or 
narrow band UVB, showed a response between 80.0% to 84.0%. Lastly in Kaposi sarcoma alitretinoin gel showed superiority to all other agents and 
better tolerance. This review highlights the benefit of timely use of vitamin A derivatives to encourage wider use. 
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INTRODUCTION 
Vitamin A has both natural and synthetic derivatives, collectively known 
as retinoids. Retinoids play an important role in embryogenesis 
(including both cell growth and differentiation) and in cellular 
inflammation. They exert their actions through binding to different 
retinoid-binding proteins and to retinoid nuclear receptors. Retinoids 
are widely used to treat a range of dermatological conditions due their 
effects on the proliferation of keratinocytes and epidermal 
differentiation [1]. The retinoids used to treat various skin diseases are 
divided into three generations. ‘First generation’ are the naturally 
occurring non-aromatic retinoids which include: Vitamin A (all-trans 
retinol), tretinoin (all-trans retinoic acid), isotretinoin (13-cis retinoic 
acid) and alitretinoin (9-cis retinoic acid). ‘Second-generation’ are the 
monoaromatic derivatives, which include: etretinate and its biologically 
active metabolite acitretin. ‘Third generation’ are the polyaromatic 
derivatives which include: adapalene, bexarotene and tazarotene [1]. 
Purpose of the review 
This review aims to highlight the positive impact of the use and/or 
early use of vitamin A derivatives, both natural and synthetic, in the 
treatment of dermatological conditions. In the authors’ local areas, 
during the past 3 y, Vitamin A derivatives were underused (table 1), 
with only isotretinoin been used. This paper aims to develop 
prescribers’ knowledge about their benefits to improve their 
usability and aids in patients scares reductions as one of the main 
goals of dermatological conditions therapeutics outcomes. 
 
Table 1: Cost of Isotretinoin provided by one CCG in west midlands with a population of 210,319 
Costs 2017 2018 2019 2020 TOTAL 
Isotretinoin 0.05%/Erythromycin 2% gel £452.16 £557.83 £514.16 £41.74 £1,565.89 
Total £452.16 £557.83 £514.16 £41.74 £1,565.89 
Items 2017 2018 2019 2020 TOTAL 
Isotretinoin 5 mg capsules 53 57 56 5 £171.00 
Total 53 57 56 5 171 
 
Mode of action 
Retinoids exert their effects by binding to retinoid-binding proteins, 
or activating, the nuclear retinoic acid receptors (RAR) and retinoid 
X receptors (RXR). Each of these receptors are composed of 3 
isotypes: α, β and γ. Both types of receptors exist together as a 
dimer. The retinoids exhibit different binding affinities and 
characteristics to both types of receptors [2]. 
Side effects 
The side effects of systemic retinoids are dose-dependent and 
resemble those seen in hypervitaminosis A. The most common are 
mucocutaneous, with chelitis being the earliest and most frequently 
observed side effect [3]. Other mucocutaneous effects include 
dryness in the oral and nasal mucosa (which might lead to epistaxis), 
dryness of the eyes, hair loss and nail fragility. Musculoskeletal 
effects include bone pain, arthralgias and myalgias. Hyperlipidaemia 
is caused by increased cholesterol and triglyceride levels and a 
reduction in HDL levels. Teratogenicity remains the most concerning 
side effect caused by retinoids. The FDA considers oral retinoids to 
be category X as they may cause foetal malformation by their effects 
on the developing central nervous system, heart, ear and thymus. 
Transient elevation in transaminase levels has been reported in 20% 
of patients, especially those treated with acitretin, and less 
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frequently those treated with isotretinoin and bexarotene [4]. In 
terms of psychiatric effects, opposing opinions exist between 
dermatologists and psychiatrists on the effect of isotretinoin in the 
occurrence of mood disorders especially depression and this topic 
has been heavily debated. Bremner et al. (2012) have demonstrated 
a link between isotretinoin and depression [5]. They provided 
evidence from case reports in the literature, temporal association, 
challenge-re-challenge studies, dose-response, biological plausibility 
and class effect. On the other hand many dermatological studies 
have suggested that the presence of acne itself causes depression 
and treating acne with isotretinoin is one way to treat depression, 
since there will be improved self-image and an overall more positive 
behaviour by the affected person [6]. Neurological effects are rare 
although symptoms of pseudotumor cerebi may occasionally occur. 
Therapeutic uses 
Acne vulgaris 
The US Food and Drug Administration (FDA) approved the medical 
use of isotretinoin in 1982. The European Directive for prescribing 
systemic isotretinoin for acne vulgaris stated in 2006, that 
isotretinoin should only be used to treat severe acne (nodular, 
conglobata) that has not responded or is not responding to 
appropriate antibiotics and topical therapy [7]. Isotretinoin (13-cis-
retinoic acid) has anti-inflammatory properties, decreases 
hyperkeratinisation which will reduce comedone formation, reduces 
production of sebum and reduces colonization of the pilosebaceous 
duct with Propionibacterium acnes [8]. P. acnes induce the immune 
response in affected patients, which results in the inflammatory 
response of acne [9]. Isotretinoin reduces Toll-like receptor-2 (TLR-
2) expression in monocytes which will result in decreasing 
inflammatory cytokine production in response to P. acnes. It was 
found that this effect continues for 6 mo after completion of therapy 
which indicates that the therapeutic effects of isotretinoin may be 
due to TLR-2 modulation [10]. 
The topical retinoids approved for acne treatment include tretinoin, 
adapalene and tazarotene. Tazorotene is currently only approved in 
the US. Topical retinoids are effective in treating mild to moderate 
acne [11]. They exert an anti-inflammatory effect in addition to 
preventing the formation of micro-comedones, the precursor lesion of 
comedones. Since each retinoid binds to different subtypes of the 
retinoic acid receptors, this leads to differences in both efficacy and 
tolerability. Tretinoin binds to all 3 subtypes (α, β and γ) of retinoic acid 
receptors, while adapalene and tazorotene only selectively bind to β and 
γ subtypes. Women of childbearing age should be counselled on topical 
retinoid therapy since Tazorotene is pregnancy category X, while 
adapalene and tretinoin are category C [12]. In a study comparing 
Tazarotene 0.1% gel to tretinoin 0.1% microsponge, tazarotene was 
found to have greater efficacy and comparable tolerability to tretinoin in 
treating mild-to-moderate inflammatory facial acne vulgaris [13]. In a 
clinical trial comparing efficacy and safety of adapalene gel 0.1% and 
tretinoin cream 0.05% in patients with mild-moderate acne, adapalene 
gel had better tolerability and equivalent efficacy compared to tretinoin 
cream over a 10week period [14]. 
Psoriasis 
The only systemic retinoid that has been approved by the FDA for 
psoriasis is acitretin. Acitretin exerts its effects by binding to all 
subtypes (α, β and γ) of RAR and RXR receptors, which result in 
reduction of the proliferation of epidermal keratinocytes. This leads 
to a decrease in erythema, desquamation and thickness of the lesion 
[15]. Acitretin is indicated in the treatment of pustular psoriasis, 
erythrodermic psoriasis and severe psoriasis that cannot be 
managed by topical treatment or phototherapy [16]. It was found in 
a randomized, double-blind, placebo-controlled study that the 
combination of acitretin and PUVA in treating severe psoriasis was 
superior to PUVA alone, achieving a 75% decrease in Psoriasis 
Severity Index and resulting in complete remission [17]. Tosti el al. 
(2009) evaluated the efficacy of acitretin in treating isolated nail 
psoriasis over a period of 6 mo. Their results showed a reduction of 
41% in the Nail Psoriasis Severity Index (NAPSI) score and they 
concluded that the reduction in NAPSI score achieved with low dose 
acitretin treatment is comparable to that achieved with the biologics 
[18]. In a study conducted on 10 patients with severe psoriasis 
receiving acitretin treatment daily, four patients had plasma 
etretinate (the teratogenic ethyl ester of acitretin) in teratogenic 
levels, this was linked to alcohol consumption which leads to re-
esterification of acitretin to etretinate. For this reason, any female of 
childbearing age receiving acitretin should be advised to continue 
using contraception for a period of 3 y, since etretinate was found to 
accumulate in the adipose tissue for a period of 18 mo post cessation 
of the treatment [19, 20].  
Tazorotene is the only topical retinoid approved for the treatment of 
psoriasis. In the UK tazorotene is indicated for treating mild to 
moderate plaque psoriasis affecting up to 10% of the surface area of 
the body, while in the US it is indicated in treating stable plaque 
psoriasis affecting up to 20% of the surface area of the body [16]. 
Tazorotene is metabolized to tazarotenic acid its active metabolite by 
estrases in the skin. It is thought that tazorotene modulates 
proliferation and differentiation of keratinocytes and also regulates 
inflammation [21]. Mason et al. conducted a meta-analysis of topical 
preparations for the treatment of psoriasis, which reported tazoretene 
to have clinical efficacy similar to potent steroids and calcipotriol [22]. 
Chronic hand eczema 
Alitretinoin was approved in the UK in 2008 for treating chronic 
hand eczema that is refractory to topical steroid treatment in 
patients who are>18 y old. It exerts its effects by binding to both 
RAR and RXR receptors. In a randomized controlled study of 
patients receiving oral alitretinoin once daily for up to 24 w, there 
was almost 50% improvement in patients with chronic hand eczema 
that was refractory to standard therapy [23, 24]. 
Photoaging and aging 
Retinoids in clinical trials have been shown to decrease the levels of 
Matrix Metallopeptidases (MMP) that are responsible for catalysing 
the degradation of collagen and elastin. They have also been 
demonstrated to increase the thickness of the epidermis which in 
turn will reduce the appearance of fine wrinkles [25]. The chemical 
structures of retinoids allow them to absorb UV radiation and trap 
free radicals, enabling them to protect cellular proteins from photo-
degradation and oxidative stress. Retinoids bind to nuclear 
receptors and modulate the expression of the genes involved in 
cellular proliferation and differentiation. Retinoids can increase the 
synthesis and decrease the degradation rate of collagen and 
hyaluronate; two important components of the dermis that are 
frequently altered and decreased by the process of aging [26]. 
Rosacea 
Topical and systemic isotretinoin can be used ‘off-label’ (outside of 
the licensed indications) in the treatment of rosacea. In a study 
conducted by Altinyazar et al. (2005) to evaluate the efficacy of 
topical adapalene gel (0.1%) and topical metronidazole gel (0.75%) 
in the treatment of papulopustular rosacea. The study showed a 
significant reduction in the total number of inflammatory lesions in 
the patients treated with adapalene, but there was no improvement 
in the scores of erythema or telangiectasia in the same group. The 
group treated with metronidazole showed improvement in the 
erythema score [27]. In a placebo-controlled, randomized clinical 
study conducted over a period of 12 w for 573 patients with rosacea 
subtype II and III, patients either received isotretinoin in 3 different 
dosages, doxycycline or placebo. The results showed a 90% 
reduction of lesions in the 0.3 mg/kg isotretinoin group while the 
doxycycline group demonstrated 83% reduction in the lesions. 
Complete remission was achieved in 24% of the patients treated 
with 0.3 mg/kg isotretinoin compared to only 14 % achieved in the 
doxycycline group. Thus, the study concluded that isotretinoin can 
be used as an alternative to oral antibiotics in the treatment of 
rosacea subtype II and III [28]. 
Lichen planus  
In a review of literature on the safety and effectiveness of topical 
retinoids in oral lichen planus patients. Sixteen studies were 
reviewed covering a total of 280 patients diagnosed with oral lichen 
planus who were treated with various classes of retinoids. The 
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review concluded that isotretinoin was the most frequently used 
retinoid. Most of the studies demonstrated clinical and 
histopathological efficacy of retinoids used in the treatment of oral 
lichen planus [29]. 
Cutaneous T-cell lymphoma (CTCL) 
In 1999 the FDA approved bexarotene for the treatment of 
cutaneous T-cell lymphoma (CTCL) that is refractory to at least one 
systemic treatment. Bexarotene exerts its effects by binding to the 
retinoid X receptor (RXR), which leads to apoptosis of CTCL cell lines 
[30]. In a multi-centre study conducted by Hamada et al. (2019) to 
evaluate the efficacy, safety and tolerability of bexarotene over 24 w, 
in 10 Japanese adults with cutaneous T-cell lymphoma (CTCL), the 
objective response rate was 53.8% [31]. Morita et al. (2020) studied 
the efficacy and safety of combination therapy with photo-
chemotherapy and bexarotene in 25 Japanese patients diagnosed 
with cutaneous T-cell lymphoma (CTCL) over 24 w. The patients 
were treated with bexarotene 300 mg and PUVA or narrow-band 
UVB. The results were reported using two different assessments: the 
modified Severity-Weighted Assessment Tool (mSWAT) and the 
Physician Global Assessment of Clinical Condition (PGA). The 
response was 80.0% (mSWAT) and 84.0% (PGA) [32]. 
Kaposi sarcoma 
In a multicentre, randomized, double-blind, controlled study that 
was conducted over a period of 12 w for 268 patients with 
cutaneous Kaposi sarcoma to evaluate the efficacy and safety of 
alitretinoin 0.1% gel, or matched vehicle with no active drug as 
control. The study results showed alitretinoin 0.1% gel was superior 
to placebo in treating cutaneous Kaposi sarcoma lesions and that 
alitretinoin was well tolerated by the patients and safe to use [33]. 
CONCLUSION 
This review demonstrates that in a wide range of dermatological 
conditions, retinoids can be highly effective and well-tolerated when 
used with an effective pregnancy prevention program. It is believed 
that if these outcomes are more widely understood and patient 
concerns are properly addressed with factual information, many 
more patients would benefit from the group of medications. 
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